<div id="readability-page-1"><div>GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Galectin announced on December 19, 2025, that “the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the Company's initial request for an in-person or teleconference meeting to a written response.&#34; The Company added that it would pursue a follow-up Type C meeting to resolve key aspects of its trial design. Based on this news, shares of Galectin fell by 28.9% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk5NzI1MjByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk5NzI1MjByMQ"/> The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.com www.schallfirm.com View source version on businesswire.com: https://www.businesswire.com/news/home/20251229972520/en/</div></div>

Galectin治療

Schall 律師事務所正在代表 Galectin Therapeutics Inc.（納斯達克代碼：GALT）的投資者調查潛在的證券法違規行為。此次調查的重點是該公司是否在其研究藥物 belapectin 方面發表了虛假或誤導性的聲明，此前在 FDA 對會議請求的回應後，股價出現了顯著下跌。遭受損失的投資者被鼓勵參與此次調查，並可以聯繫該事務所以獲取更多信息

GALT 投資者有機會與 Schall 律師事務所一起參與 Galectin Therapeutics Inc.的欺詐調查